



Dr. Ashok Ajmera (FCA), CMD & CEO

Dr. Ashok Ajmera's column as on February 29, 2020

Menace of Coronavirus creates blood bath across global markets; all eyes on key developments related to Coronavirus, movement of crude oil price and rupee against the US\$..

Global sentiments were shattered as more and more Coronavirus/COVID-19 cases were reported outside of China on daily basis. Health officials across the globe are finding it difficult to contain the virus, which can cause a potentially deadly pneumonia-like illness in a minority of patients and spread from others who look healthy. The World Health Organization has not yet declared COVID – 19 as pandemic.Fear of COVID-19 turning out to be pandemic has disrupted global supply chain and will eventually affect global economic outlook. As a result, Indian benchmark indices witnessed a fall of 7 percent which its worst weekly fall since 2009. The Sensex declined steeply by 2,872.83 points (7 percent) to end at 38,297.29 in the past week, while the Nifty registered a fall of 879.05 points (7.3 percent) to end at 11,201.8.

All sectoral indices on the NSE ended deep in the red. Nifty IT index dropped over 5 per cent to 15,274 levels while Nifty Metal index cracked over 7 per cent to 2,233 levels. In the broader market, the S&P BSE MidCap index dropped over 3 per cent to 14,600 levels while S&P BSE SmallCap ended at 13,709, down 500 points or 3.52 per cent.

Another negative point was steep fall in growth of GDP in October-December quarter of 2019-20. India's GDP grew 4.7 percent as against 5.6 percent in the corresponding quarter of 2018-19 which is quarterly lowest growth since 2013. Looking ahead, gross domestic product (GDP) growth is set to stagnate at 4.7 per cent in the March quarter (Q4) too, according to the annual estimate by the National Statistical Office (NSO). Even in annual terms, investment is set to show a contraction of 0.6 per cent, according to the second



advance estimate for FY20 released by the NSO. Manufacturing is set to show 0.9 per cent growth, the lowest since 2012-13 in the current GDP series.

Domestic Institutional Investors (DIIs) bought equities worth of Rs. 15,985.82 crore, while foreign institutional investors (FIIs) sold equities worth Rs. 11,368.67 crore.

For the week, the rupee slipped 53 paise at 72.17 on February 28 against February 20 closing of 71.64.

Global markets

Global equities too were headed for their worst week since the depths of the 2008 financial crisis as investors ditched risky assets on fears the coronavirus would become a pandemic and trigger a global recession. US equities led the rout as the S&P 500 fell 4.42 per cent, its largest percentage drop since August 2011. It has lost 12 per cent since hitting a record close on Feb. 19, marking its fastest correction ever in just six trading days while the Dow Jones Industrial Average fell 1,190.95 points, its biggest points drop ever.

Official gauges of China's factory and non-factory activity plunged to record lows in February as the nation's economy struggled to resume normal production as it faced the coronavirus epidemic. China is not only the world's second largest economy, but also the largest industrial country, the largest foreign exchange reserve country, and the largest contributor to global economic growth. Stock futures showed European indexes set to track the rout in their Asian counterparts on Friday, which comes after another massive selloff on Wall Street overnight. MSCI's regional index excluding Japan shed 2.7 per cent. Japan's Nikkei slumped 4.3 per cent on rising fears the Olympics planned in July-August may be called off due to the coronavirus. As investors moved to the safety of high-grade bonds, U.S. bond yields have plunged, with the benchmark 10-year notes yield hitting a record low of 1.241 per cent. It last stood at 1.274 per cent.

Crude oil

In commodities, US crude futures fell 3.2 per cent to US\$45.59 per barrel, having lost 14.5% so far on the week, which would be the deepest fall in nearly nine years.

Ajcon's view

COVID-19/Coronavirus has been spreading at a rapid pace and has made us cautious on equities for the moment. Any news on the resolution of the same through discovery of a drug or fall in number of COVID cases globally would improve the sentiments. At the present juncture, catching a falling knife can be hazardous as COVID-19 can turn out to be pandemic unless there is some drug discovery to arrest it. However, at the same time, we continue to believe in the old maxim of Legendary investor – Mr. Warren Buffet "Be fearful when others are greedy and greedy when others are fearful". In line with this old maxim, investors can chase Companies which have delivered robust 9MFY20 performance and can benefit from the current environment. Indian companies, can take advantage of the supply chain disruption in China. We believe, it would be prudent for investors to look out for quality picks which have a robust business model, quality growth, consistent earnings although may be affected in the current economic downturn but proved its mettle over the years, business model suited to changing dynamics of the economy, cashflow visibility, low debt, no pledge of promoter holdings and backed by quality management especially on the corporate governance front.



Disclaimer

Ajcon Global Services Ltd. is a fully integrated investment banking, merchant banking, corporate advisory, stock broking, commodity, and currency broking. Ajcon Global Services Ltd. research analysts responsible for the preparation of the research report may interact with trading desk personnel, sales personnel and other parties for gathering, applying and interpreting information.

Ajcon Global Services Ltd. is a SEBI registered Research Analyst entity bearing registration Number INH000001170 under SEBI (Research Analysts) Regulations, 2014.

Individuals employed as research analyst by Ajcon Global Services Ltd. or their associates are not allowed to deal or trade in securities that the research analyst recommends within thirty days before and within five days after the publication of a research report as prescribed under SEBI Research Analyst Regulations.

Subject to the restrictions mentioned in above paragraph, we and our affliates, officers, directors, employees and their relative may: (a) from time to time, have long or short positions acting as a principal in, and buy or sell the securities or derivatives thereof, of Company mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage.

Ajcon Global Services Ltd. or its associates may have commercial transactions with the Company mentioned in the research report with respect to advisory services.

The information and opinions in this report have been prepared by Ajcon Global Services Ltd. and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of Ajcon Global Services Ltd. While we would endeavour to update the information herein on a reasonable basis, Ajcon Global Services Ltd. is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent Ajcon Global Services Ltd. from doing so. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. Ajcon Global Services Ltd. will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. Ajcon Global Services Ltd. accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Ajcon Global Services Ltd. or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.



Ajcon Global Services Ltd. encourages independence in research report preparation and strives to minimize conflict in preparation of research report. Ajcon Global Services Ltd. or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither Ajcon Global Services Ltd. nor Research Analysts have any material conflict of interest at the time of publication of this report.

It is confirmed that CA Ashok Ajmera or any other Research Analysts of this report has not received any compensation from the company mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

Ajcon Global Services Ltd. or its subsidiaries collectively or Directors including their relatives, Research Analysts, do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

It is confirmed that CA Ashok Ajmera research analyst or any other Research Analysts of Ajcon Global do not serve as an officer, director or employee of the companies mentioned in the report.

Ajcon Global Services Ltd. may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor Ajcon Global Services Ltd. have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on Ajcon Global Services Ltd. by any Regulatory Authority impacting Equity Research Analysis activities.

Analyst Certification

I, CA Ashok Ajmera, research analyst, author and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject securities. I also certify that no part of compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view (s) in this report.



For research related queries contact:

Mr. Akash Jain - Vice President (Research) at research@ajcon.net

CIN: L74140MH1986PLC041941

SEBI registration Number: INH000001170 as per SEBI (Research Analysts) Regulations, 2014.

Website: www.ajcononline.com

Registered and Corporate office : 408 - (4th Floor), Express Zone, "A" Wing, Cello – Sonal Realty, Near Oberoi Mall and Patel's, Western Express Highway, Goregaon (East), Mumbai – 400063. Tel: 91-22-67160400, Fax: 022-28722062